Atlas Trials

Criterium, Inc.

13 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Criterium, Inc.

RecordFirmDate
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer (NCT06992258)Criterium, Inc.2025-10-27
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (NCT05458674)Criterium, Inc.2024-01-30
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. (NCT05230810)Criterium, Inc.2022-08-25
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis (NCT05180422)Criterium, Inc.2022-06-15
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC (NCT04739358)Criterium, Inc.2022-05-25
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer (NCT04791384)Criterium, Inc.2022-04-21

Track Criterium, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.